The analysis only reflected the effectiveness evidence from 1 RCT of 4 included in the clinical review and was assessed as directly applicable with potentially serious limitations. The committee were concerned that the time horizon of this economic evaluation is short and therefore does not capture the longer term costs and effects of treatment. The trial with the longest follow-up included in the clinical review was CONFIRM-HF, which had a 12 month follow up. This trial implemented different dosing regimes of 500mg or 1000mg of iron given per visit compared to 200mg per visit as in the other included trials. Unit costs of IV iron were presented to the committee for consideration of the costs and cost effectiveness associated with different dosing regimes. The mean total dose in CONFIRM-HF trial was 1500mg over 1 year. The unit cost per milligram of iron is the same between the 100mg and 500mg vial sizes; however, the 500mg dosing regime (as in CONFIRM-HF) requires significantly fewer visits than the 200mg dosing regime and is therefore less costly. The committee also noted that such a regime is likely to be more acceptable to people due to the fewer number of visits. It was noted that this dosing regime is similar to current clinical practice in the NHS for people receiving IV iron therapy (for example, anaemic patients with CKD). The committee therefore considered the cost effectiveness of IV iron supplementation based on the clinical evidence of CONFIRM-HF with a different dosing regime and longer follow-up. The committee noted that all- Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 cause hospitalisation event rates in CONFIRM-HF were similar to those of FAIR-HF. 